What Цитрамон Treats: Main Uses and Benefits

Цитрамон (Citramon) is commonly used to provide symptomatic relief across multiple domains of discomfort, targeting symptom clusters that may interfere with daily functioning. The combination is relevant when short-term symptomatic assistance is needed to ease the overall burden of symptoms associated with acute episodes. The application is relevant for managing symptoms of headache, muscular aches, toothache, and menstrual cramps.

The use is relevant for addressing symptoms related to physical discomfort and systemic imbalance. It is often used during phases when symptoms become more noticeable, such as during acute attacks of migraine or periods of heightened discomfort from fever syndrome associated with colds. The medication contributes to general well-being during symptomatic phases and may assist patients with coping more steadily with symptom fluctuations.

“This therapeutic approach is relevant in contexts marked by increased discomfort or tension, supporting the patient during difficult episodes by easing distress.”

---

Quick Fact: Relief for Episodic Discomfort

This product is commonly used across conditions presenting with acute episodes of mild to moderate pain, may assist with maintaining functional stability when symptoms interfere with routine activities.

---

Key Therapeutic Domains

• Pain Relief: Addresses symptoms related to headache (including migraine), toothache, and recurrent pain like menalgia and neuralgia.
• Fever Management: Is used for managing elevated body temperature and associated systemic discomfort, such as generalized body aches during infectious illnesses.
• Musculoskeletal Support: Contributes to supportive relief for localized pain associated with muscle aches and minor joint discomfort.

Regulatory References

1. NIH DailyMed drug label

Eligibility Profile: Official Regulatory Status

Цитрамон is a fixed-combination product containing Acetylsalicylic Acid (Aspirin), Acetaminophen (Paracetamol), and Caffeine, and its eligibility is determined by the contraindications for each component as documented in official government sources.

Contraindicated Populations	Use Restriction
Known allergy to Aspirin, Acetaminophen, or Caffeine, or history of NSAID-induced reactions (e.g., asthma, urticaria).	Absolute Prohibition
Active peptic ulcers, gastrointestinal bleeding (current or history), or hemorrhagic diathesis.	Absolute Prohibition
Severe hepatic (liver) or severe renal (kidney) impairment or failure.	Absolute Prohibition

Age and Physiological Restrictions

• Pediatric Use: The product is contraindicated in children and adolescents, typically under 15 or 18 years of age. This restriction is primarily due to the risk of Reye's syndrome when Aspirin is given during or recovering from viral illnesses like flu or chickenpox.
• Pregnancy Status: Use is absolutely contraindicated during the third trimester of pregnancy. Use in the first and second trimesters is only permitted when strictly necessary and under professional guidance.
• Breastfeeding: The product components pass into breast milk; official labeling advises caution, and use is generally not recommended or requires the discontinuation of nursing.

Conditional Use

Patients with mild-to-moderate liver or kidney problems, chronic alcohol consumption, or a history of stomach ulcers must use this product only with extreme caution and under medical supervision.

Interactions with other medicines and products

Official regulatory documentation identifies specific patterns of interaction based on the components of Citramon (Acetaminophen, Acetylsalicylic Acid, Caffeine).

Formal Interaction Restrictions

Co-administration is contraindicated with any other medicinal product containing Acetaminophen (Paracetamol) due to the risk of severe liver toxicity. Use is also restricted with Monoamine Oxidase Inhibitors (MAOIs).

---

Documented Interaction Patterns

Interacting Substance/Class	Official Interaction Pattern	Consequence
Other NSAIDs / Anticoagulants	Pharmacodynamic additive effect	Increased risk of severe gastrointestinal bleeding.
Alcohol (Ethanol)	CYP2E1 enzyme induction	Increased risk of Acetaminophen-induced hepatotoxicity.
Tobacco Smoking	CYP1A2 enzyme induction	Increased clearance, reduced exposure of the Caffeine component.
Tizanidine	CYP1A2 competitive metabolism	Increased plasma exposure of Tizanidine.
Antacids / Absorbents	Altered excretion mechanism	Reduced exposure of the Acetylsalicylic Acid component.

---

Population-Dependent Considerations

The risk of the interaction consequence, specifically severe gastrointestinal bleeding, is officially noted as being higher for individuals aged 60 years or older and those with a history of stomach ulcers or bleeding problems when co-administered with other risk factors. Furthermore, caffeine-containing beverages may result in additive effects like excessive stimulation.

Central and Peripheral Enzyme Inhibition

This primary domain involves the action of Acetylsalicylic Acid as an irreversible inhibitor of the Cyclooxygenase (COX-1 and COX-2) enzymes, which are essential for producing chemical mediators called prostaglandins. This molecular blockade leads to a sharp reduction in prostaglandin signaling, directly dampening the sensitization of peripheral pain receptors and resetting the hypothalamic set-point for core body temperature, thereby initiating the modulation of pain signal transmission and temperature regulation.

---

CNS Pathway Control and Thermoregulation

The mechanism is completed by Acetaminophen, which exerts its primary influence within the Central Nervous System (CNS). It functions as an inhibitor of central COX activity and its metabolite may modulate TRPV1 receptors, which modulates the descending pain signals and influences temperature regulation pathways. This action helps to limit the transmission and perception of discomfort signals once they reach the brain and spinal cord, shaping the resulting central pain processing dynamics.

---

Synergy via Adenosine Receptor Antagonism

The three-component mechanism is strengthened by Caffeine, which acts as a non-selective antagonist at inhibitory Adenosine Receptors in the CNS. This engagement of a separate neurotransmitter system results in the pharmacodynamic potentiation of the primary agents, contributing to cerebral vasoconstriction and influencing the rate and intensity of the subsequent physiological modulation.

Official Administration Guidelines

The combination product Цитрамон is administered exclusively via the oral route as a solid dosage form (tablet or caplet). The official instructions for proper use mandate that the medication is swallowed with a full glass of water and may be taken with or without food.

---

Dosing and Frequency

Official dosing recommendations are defined by the specific formulation strength. For the strength containing Acetaminophen 250 mg / Aspirin 250 mg / Caffeine 65 mg, the standard initial dose is 2 tablets taken every 6 hours as needed. The maximum allowed dose is 8 tablets in a 24-hour period. An alternative formulation uses a lower strength, typically administered as 1 tablet up to three times per day, with a mandatory minimum interval of 6 to 8 hours between doses. The use pattern is strictly defined as intermittent, acute use for symptomatic periods, not long-term daily consumption.

---

Administration Constraints and Population Rules

Usage protocol requires patients to avoid simultaneous administration with any other product that contains acetaminophen due to the risk of exceeding the total systemic limit for that component. Furthermore, official guidance states that external consumption of caffeine from other sources must be limited. This combination is generally approved for use in adolescents, typically those 12 years of age and older, depending on the specific formulation strength marketed.

Research Evidence / Overview of Studies for Цитрамон

---

Evidence for Use in Acute Migraine Attacks

Research for the three-component combination in acute migraine attacks has been evaluated in multiple large-scale Randomized Controlled Trials (RCTs), Systematic Reviews, and Meta-analyses. These studies were used in research exploring how symptoms change over time and often included adult patients with migraine who presented with pain classified as moderate to severe. Researchers monitored patient-reported outcomes describing perceived discomfort, primarily focusing on two key outcomes: the time elapsed until a patient became completely pain-free and the proportion of patients who achieved pain reduction (to mild or none) within a few hours. Studies exploring short-term symptom changes reported that the findings describe patterns observed in the studies when compared against control groups, such as placebo.

---

Evidence for Use in Episodic Tension-Type Headache

The evidence for the combination's use in episodic tension-type headache primarily relies on Randomized Controlled Trials (RCTs) and reviews that synthesize trial data. These studies explored symptom patterns in outpatients who experienced conditions characterized by episodic manifestations. The main outcomes monitored included reaching pain-free status at defined time intervals and measuring the degree of overall change in measured outcomes related to physical discomfort achieved. Reports documented measurements on the time until observed change in symptom intensity in the study populations.

---

Research Gaps and Areas of Uncertainty

The majority of clinical trials conducted for the triple combination medicine have involved short-term observation with limited follow-up durations. Consequently, long-term effects are not fully established. Research highlights what is known—that the available evidence provides insight into short-term changes—but there is limited information regarding the potential for sustained effects or effects that extend beyond the immediate treatment period. Furthermore, data for special populations such as adolescents or older adults with specific comorbidities are still emerging. A documented research concern that remains uncertain involves understanding patterns related to the risk of developing medication-overuse headache that was associated with frequent administration in some studies.

Key Studies & References

1. Clinical Guideline: Pharmacological Management of Acute Migraine
2. DailyMed: Aspirin, Acetaminophen, and Caffeine Tablet Official Drug Label (Regulatory Monograph)

Common questions about Цитрамон (FAQ)

Q: Can Цитрамон help with toothaches?

According to the official product information, Цитрамон is indicated for the short-term symptomatic treatment of mild to moderate pain. This official indication includes conditions such as toothache, as well as various types of headaches.

Q: How long does the effect of Цитрамон last?

Official regulatory guidelines and dosing instructions typically recommend taking the medication every six hours as needed for pain relief. The dosing schedule suggests the duration of time that relief may be observed.

Q: Can I take Цитрамон if I have high blood pressure?

Official safety documentation advises caution for individuals with pre-existing heart conditions. The product is strictly contraindicated, meaning it must not be used, if a person has diagnosed severe heart problems or severe heart failure.

Q: What if I forget to take Цитрамон when I need it?

Regulatory-sourced advice for medications of this type generally suggests skipping the forgotten dose. Guidance suggests resuming the regular dosing schedule and avoiding taking an extra dose to make up for the one that was missed.

Q: Can Цитрамон be taken during a menstrual period?

Yes, official regulatory documentation describes this product as being intended for the short-term symptomatic treatment of painful menstruation. This is one of the listed uses for which the medicine is officially indicated.

Q: Does Цитрамон interact with common supplements like Vitamin C?

Official documentation lists several known interactions with other drugs and substances, such as alcohol and certain other pain relievers. However, the regulatory information regarding potential drug interactions does not specifically list an interaction with the common supplement Vitamin C (Ascorbic Acid).

Q: Is it okay to take Цитрамон if I already take a heart medication?

Official warnings state the product should not be used if a person has severe heart problems. Additionally, due to the aspirin component, patients taking anticoagulants (blood thinners) have an increased risk of severe bleeding.

Q: Is it true that Цитрамон is sold under different names internationally?

The product is classified as a fixed-dose combination medicine, containing Acetaminophen, Aspirin, and Caffeine. While this specific triple-component formulation is common for pain relief, official trade names and specific branding often vary significantly based on the country or region of sale.

How to Store and Dispose of Цитрамон?

The storage and disposal of Цитрамон (Tsitramon) must strictly follow official governmental regulatory requirements to maintain product stability and ensure safety.

---

Official Storage Requirements

Temperature and Environment: Store the tablets in a dry place at a temperature not exceeding 25 C. The product must be protected from moisture and kept in its original package.

Child Safety: It is mandatory to keep Цитрамон out of the sight and reach of children to prevent accidental exposure.

---

Disposal Instructions

Pharmaceutical Waste: Unused or expired medication must not be disposed of via household waste or the sewer system. Dispose of the product by returning it to a designated pharmacy or collection point, as required by local pharmaceutical waste regulations.